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as the controversy over the requirement
for a defective p53 pathway to support
the replication selectivity of ONYX-015—
stimulated the development of numerous
additional oncolytic virus platforms. The
controversy surrounding the inactivated-
p53 requirement for ONYX-015 replica-
tion has been somewhat resolved
through studies demonstrating that a
subset of tumor cells contain a wild-type
p53 gene, yet are functionally p53 inac-
tive, due to inactivation of the “upstream”
p14arf, resulting in the accumulation of
mdm2, which binds p53 and targets it for
degradation, much in the same way as
does the adenovirus 55K protein
(McCormick, 2000; Ries et al., 2000).
While improved conditionally replicative
adenoviruses like ONYX-411 and others
(Li et al., 2001; Ramachandra et al.,
2001) have been developed, the ques-
tion still remains whether oncolytic
agents developed from other virus gen-
era will be more efficacious for local-
regional or systemic applications.Table 1
summarizes some other viruses in devel-
opment. The properties of these viruses
in terms of the expression of their cog-
nate receptors on various tumor cell
types, reproductive cycle time, yield,
cytotoxicity, and selectivity cover a broad
spectrum. Importantly, the issue of virus-
specific immune responses will need to
be addressed in order to repeatedly
administer any of these viruses intra-
venously. Another important issue relat-
ed to some of these viruses may be their
possible safety risk; in several instances,
viruses are being used without genetic
modification—such as deleting critical
virus regulatory genes—suggesting the
possibility of in vivo selection of virulent
phenotypes. For these or any oncolytic
viruses to eventually gain FDA approval
and become the standard of care will
require continued refinement and test-
ing, both in preclinical models and in
safety and efficacy trials in humans.
Nevertheless, the complete makeover
that ONYX-015 has received in the
design and development of ONYX-411
would appear to be a step in the right
direction toward oncolytic viruses
becoming useful therapies for the treat-
ment of selected cancers.
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For decades we have been attempting to
understand the basis of drug resistance
manifested by so many cancers. Even
tumors never previously exposed to anti-
cancer agents often already show intrin-
sic drug resistance, suggesting that
gene mutations driving tumor develop-
ment do not automatically confer resis-
tance to anticancer agents. In two recent
papers, Lowe and collaborators (Schmitt
et al., 2002a, 2002b) convincingly show
that in a lymphoid mouse tumor model,
drug resistance can be conferred not
only by lesions in the apoptotic pathway
but also, surprisingly, by mutations in the
senescence pathway. The realization
that an intact senescence pathway can
contribute to the success of chemothera-
py may have profound consequences for
the treatment of cancer patients.
Several mechanisms can contribute
to drug resistance. Cytotoxic drugs, at
the moment still the backbone for treat-
ment of disseminated cancer, almost
invariably damage DNA or interfere with
DNA replication or chromosomal segre-
gation. One way cells can prevent killing
by anticancer drugs is to expel the drugs
from the cell by transporters. Even low
amounts of these transporters substan-
tially decrease the sensitivity of cells to
cytotoxic drugs (Allen et al., 2000, and
references therein). However, this does
not explain why tumors often are inher-
ently resistant to anticancer agents. One
has to assume that this tolerance arises
as a side effect of the genetic alterations
that drive the tumorigenic process.
Indeed, mutations interfering with apop-
tosis can contribute both to tumor growth
and confer resistance to chemotherapy
in a mouse lymphoma model (Schmitt et
al., 1999). However, clinical practice
teaches that tumors with clear defects in
the apoptotic machinery are not neces-
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sarily more resistant to anticancer drugs,
and therefore, skepticism about the con-
tribution of mutations in the apoptotic
pathways to chemotherapy resistance is
justified (Borst et al., 2001; Brown and
Wouters, 1999). This skepticism was
also fostered by observations from
clonogenic assays, which showed that
defects in the apoptotic pathway did not
necessarily reduce the number of surviv-
ing cell clones in response to treatment
even though short-term cell survival was
markedly reduced (Brown and Wouters,
1999; Schmitt and Lowe, 2002).
Therefore, cells saved from early apopto-
sis would subsequently die anyway as a
consequence of mitotic catastrophe.
Finally, there is always the question
whether drug resistance observed
in a murine lymphoma model has
any bearing on tolerance mecha-
nisms in other cell types and, even
more important, in other species.
The two recent papers by Lowe’s
group (Schmitt et al., 2002a, 2002b)
not only highlight the role of apopto-
sis in preventing Eµ-Myc-induced
lymphomagenesis, they also reveal
an unsuspected role of the senes-
cence pathway in the resistance to
the DNA methylating drug
cyclophosphamide (CTX). An intact
senescence pathway appears piv-
otal for the efficacy of CTX, and its
disruption makes tumor cells highly
refractory to the drug.
The Lowe group utilized the
well-established Eµ-Myc tumor
model to study response to
chemotherapy (Schmitt et al., 1999).
In this model, loss- or gain-of-func-
tion mutations that block apoptosis
(p53 loss, Bcl2 overexpression)
cause lymphoma acceleration. p53
deficiency shows the most potent
synergy with the Eµ-Myc transgene.
Bcl2 overexpression in Eµ-Myc;p53−/−
cells confers virtually no additional
advantage to the tumor cells, and such
advantage is even fully absent when a
construct encoding a dominant-negative
caspase-9 is introduced, indicating that
loss of p53 does it all. Interestingly, while
tumors arising in Eµ-Myc;p53+/− com-
pound mice invariably lose the remaining
functional p53 allele, this does not occur
when Bcl2 is simultaneously overex-
pressed, illustrating that blocking of the
apoptotic pathway represents the prima-
ry driving force for loss of the remaining
wt p53 allele in these lymphomas
(Schmitt et al., 2002a). The Bcl2-overex-
pressing tumors nevertheless differ from
the tumors with disrupted p53 in that the
former remain pseudo-diploid, whereas
the latter are aneuploid. However, this
aneuploidy does not appear to add to the
growth and metastatic potential of the
lymphomas, arguing that the genetic
instability seen in these Eµ-Myc;p53−/−
tumors is not an important factor con-
tributing to tumor progression.
When Eµ-Myc overexpression was
combined with disruption of both the
p19Arf and p16Ink4a genes, tumors devel-
oped after a short latency as previously
reported (Schmitt et al., 1999).
Inactivation of p19Arf but not p16Ink4a is
responsible for the synergy with Eµ-Myc
in accelerating lymphomagenesis
(Eischen et al., 1999). This situation dif-
fers from that in other tumor models in
which p16Ink4a loss does contribute to
tumor development (Krimpenfort et al.,
2001; Randle et al., 2001; Sharpless et
al., 2001). p19Arf loss likely exerts its
oncogenic effect in this model by pre-
venting induction of p53 as a result of
aberrant oncogene expression. It is
worth noting that this tumor-suppressor
activity of p19Arf is not seen in an epithe-
lial tumor model where p19Arf loss fails 
to abrogate oncogene-induced p53-
dependent apoptosis (Tolbert et al.,
2002). Overexpression of Bcl2 in Eµ-
Myc;p19Arf−/− lymphoma cells augments
tumorigenesis and leads to comparable
tumor characteristics with respect to
latency and malignancy as observed for
Eµ-Myc;p53−/− cells. A similar effect of
Bcl2 is seen in Eµ-Myc;p16Ink4a−/−;p19Arf−/−
cells.
The surprise came when the various
mutants were treated with CTX. As
shown by elegant in vivo imaging, Eµ-
Myc tumors rapidly regressed and the
majority of the mice survived long term.
By contrast, both Eµ-Myc;Bcl2 and Eµ-
Myc;p53−/− tumors invariably progressed,
albeit with distinct initial kinetics. As might
have been predicted, Eµ-Myc;p19Arf−/−
tumors responded equally well to CTX
as the Eµ-Myc tumors. Most interest-
ingly, however, Eµ-Myc;p16Ink4a−/−;p19Arf−/−
tumors appeared highly refractory to
therapy and progressed rapidly,
albeit somewhat slower than Eµ-
Myc;p53−/− tumors. A retrovirally
introduced Bcl2 gene had no impact
on the overall survival of the p53 null
group, whereas it accelerated tumor
formation in the p16/p19 null group
up to the level of the p53 null cohort.
This indicates that p16Ink4a, which
itself does not influence tumor initia-
tion and progression of B lym-
phomas, is a key factor in the
response to CTX of this tumor. In
accordance with this notion, p16Ink4a
is upregulated in CTX-treated Eµ-
Myc;Bcl2;p19Arf−/− tumors with the
concomitant appearance of “mark-
ers of senescence.” Utilizing a set of
elegant genetic approaches (LOH of
the common exon 2 of the
p19Arf/p16Ink4a locus; specific inacti-
vation of p16Ink4a by antisense) Lowe
and coworkers went on to show that
p16Ink4a is responsible for this CTX
resistance. Furthermore, p16Ink4a
requires functional p53 for this in
vivo senescence induction as was
previously observed in mouse fibroblasts
in culture.
These analyses show that, in this
lymphoma model, at least two responses
contribute to the cytotoxic therapy: the
apoptotic pathway and the senescence
pathway (Figure 1). The contribution of
the latter is substantial and emphasizes
the need to identify targets of p16 and/or
p53 that impinge on the senescence
response. These targets might well be
known components of the cell cycle
machinery, such as p21 and pRb, but
their specific contribution to senescence,
apoptosis, and mitotic catastrophe in
response to different cytotoxic drugs
Figure 1. Cellular senescence and cancer therapy
Model of therapy-induced senescence controlled by
p16INK4a and p53. Cyclophosphamide causes DNA
damage, which activates p53 through a p19ARF-inde-
pendent mechanism. Block of p53-dependent and -
independent apoptotic pathways by Bcl2 uncovers
senescence as a drug-induced response program.
Senescence is disrupted in the context of p53 or
p16Ink4a/p19Arf loss, whereas p19Arf deficiency alone is
not sufficient to disable senescence. p16INK4a, like p53,
can be induced by DNA-damaging treatment and
probably cooperates in a common arrest program
(figure and legend from Schmitt et al., 2002b).
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clearly needs to be further defined (Bunz
et al., 1998; Wouters et al., 1999).
The current studies also provide a
framework for why mutations only affect-
ing the apoptotic pathway do not neces-
sarily correlate with a poor prognosis.
These mutations might have prevented
the occurrence of other lesions, such as
in p53, which are in fact more harmful
because they could mitigate the efficacy
of anticancer agents. The observations
reported in these two papers (Schmitt et
al., 2002a, 2002b) also argue that the
genomic instability that is concurrent
with p53 deficiency in this system does
not significantly contribute to tumor initia-
tion and progression but rather is an
accidental side effect that nevertheless
may have major consequences for the
efficacy of subsequent treatment.
The obvious question that remains is
how senescence plays out against apop-
tosis and mitotic catastrophe in the erad-
ication of various tumors by anticancer
agents. The CTX-induced senescence
was most pronounced in the absence of
apoptosis. Hence, the relative role of
senescence in drug treatment sensitivity
likely depends on the cell type, the
genetic lesions that drove tumor devel-
opment, and last but not least, the anti-
cancer agent itself. Studies in other sys-
tems support this (Bunz, 1999).
Therefore, we must understand the inter-
play between these lesions and their
impact on the various resistance mecha-
nisms. Only then can we offer patients—
after appropriate molecular characteriza-
tion of the tumor—the tailored treatment
that takes into account tumor-specific
resistance mechanisms similar to those
described by Lowe and collaborators.
Induction of senescence offers at least
an appealing new option to include as a
strategy for intervention.
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The p53 tumor-suppressor protein, first
identified in 1979, acts as a major node
in a complex network evolved to sense
diverse cellular stresses including DNA
damage and hyperproliferative signals
(Ko and Prives, 1996). Once stabilized
and activated by genotoxic stress, p53
can either activate or repress a wide
array of different gene targets, which in
turn can regulate cell cycle, cell death,
DNA repair, angiogenesis, and other out-
comes. p53 functions, including apopto-
sis, are thought to require its sequence-
specific DNA binding and transcriptional
activation activities, and a number of
apoptosis-related genes are induced by
p53 activation (Johnstone et al., 2002).
Consequently, p53 is reported to be
functionally inactivated in more than half
of all human tumors, and murine models
have confirmed p53’s central role in
tumorigenesis. Furthermore, the majority
of tumor-associated p53 mutations occur
in the core DNA binding domain and pre-
vent interaction with target sequences.
The cloning in the late 1990s of two p53-
related genes, p63 and p73, caused a
great excitement within the cancer biolo-
gy community with the prospect of two
additional tumor suppressors (Yang and
McKeon, 2000). Initially the family
resemblance was striking. p63 and p73
share with p53 an amino-terminal trans-
p53 leans on its siblings
Despite the common assumption that p53 by itself can induce apoptosis, results of a recent study implicate the homolo-
gous genes p63 and p73 in p53-mediated programmed cell death.
